Silexion Therapeutics Corp Ordinary Shares (SLXN) Stock Price
SLXNStock
$0.36−99.49%52W
Market Cap$2.03M
P/E—
PEG Ratio—
Div yield—
Beta-0.27
SLXN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-108.92%
Price vs S&P 500 (4W)-88.05%
VGM Score2.83
SLXN Earnings Surprise History
Q3 25-28.80est. -34.00
Q1 26-8.50est. -12.90
Q2 26-5.17est. -2.12
SLXN Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.13
4.13
4.00
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SLXNSilexion Therapeutics Corp Ordinary Shares | — | — | F | $0.36 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Silexion Therapeutics Corp Ordinary Shares
Silexion Therapeutics is a clinical-stage biotechnology company developing targeted treatments for KRAS-driven cancers. Its lead product candidate, SIL204, is a locally administered siRNA designed to treat locally advanced pancreatic cancer in combination with standard chemotherapy, specifically targeting tumors with KRAS G12D and G12V mutations. The company focuses on non-resectable cases where surgical removal is not possible.